TITLE:
Primary Raynaud’s Syndrome: An Intrinsic Autoimmune Disease that Is Amenable to Mycophenolate Mofetil
AUTHORS:
Kamel El-Reshaid, Shaima Al-Bader
KEYWORDS:
Raynaud’s Syndrome, Mycophenolate Mofetil, Treatment, Autoimmune, Idiopathic
JOURNAL NAME:
Case Reports in Clinical Medicine,
Vol.13 No.11,
November
21,
2024
ABSTRACT: Raynaud’s syndrome (RS) is a vasospastic disorder with potential hereditary predisposition and multiple triggering factors. After the exclusion of external stimuli and local disorders, autoimmunity presents a potential intrinsic trigger even in idiopathic RS. We present a 47-year-old woman with severe and progressive RS in both hands and toes for 2 years. She did not have: a) clinical and laboratory evidence of systemic autoimmune diseases; b) prior drug exposure; c) local digits disease. She could not tolerate vasodilators. Since she had elevated C-reactive protein, she received MMF as immunosuppressive therapy. Within 2 weeks, her symptoms improved, and she remained disease-free for 2 years. In conclusion, blocking intrinsic autoimmune triggers with MMF is a safe, practical, and effective short- and long-term treatment for refractory primary RS.